Core Viewpoint - Junshi Biosciences has raised approximately HKD 1.026 billion through a discounted placement of H-shares, reflecting significant cash flow pressures and concerns regarding the sustainability of its financing and R&D model [2][4]. Financing and Capital Structure - The recent placement at HKD 25.35 per share represents an 11.52% discount, marking the largest discount financing in the Hong Kong biopharmaceutical sector this year [2]. - This is the third large-scale financing for Junshi Biosciences in four years, with total fundraising since 2021 reaching approximately RMB 7 billion [3]. - The company has accumulated losses exceeding RMB 10.9 billion since its establishment in 2012, with R&D expenditures totaling RMB 11.419 billion, indicating a heavy reliance on external capital [4]. Financial Performance and Ratios - Junshi's asset-liability ratio increased from 24.64% in 2021 to 47.98% in Q1 2025, indicating rising financial pressure [5][6]. - The company's liquidity ratios have declined significantly, with the current ratio dropping to 1.40 and the quick ratio to 1.20 in Q1 2025, both below industry averages [6][8]. - Cash reserves have decreased from a peak of RMB 6.031 billion at the end of 2022 to RMB 2.522 billion by Q1 2025, a reduction of over 58% [5]. Revenue and Product Dependency - Junshi's revenue heavily relies on its core product, Toripalimab (Tuoyi®), which accounted for over 88% of total revenue in Q1 2025, despite the company still facing losses [9][10]. - The company reported a total revenue of RMB 1.948 billion in 2024, with a net loss of RMB 1.281 billion, although the loss narrowed by 43.90% year-on-year [9]. - International revenue has fluctuated dramatically, dropping from RMB 3.341 billion in 2021 to RMB 0.093 billion in 2024, highlighting instability in the company's revenue structure [10].

Core Viewpoint - The company is preparing for the 2024 Annual General Meeting (AGM) to ensure the rights of shareholders and maintain order and efficiency during the meeting [1][2][3] Group 1: Meeting Procedures - Only eligible shareholders, directors, supervisors, senior management, and other attendees can participate in the AGM, and the company reserves the right to refuse entry to those who do not meet the criteria [2] - The meeting will follow the agenda as notified, and no agenda items can be postponed or omitted from voting [2] - Attendees must maintain order and respect the rights of other shareholders during the meeting, with the company authorized to take measures against disruptions [2][3] Group 2: Shareholder Rights - Shareholders have the right to speak, inquire, and vote during the AGM, with a maximum speaking time of five minutes per shareholder [3] - The meeting will be witnessed by a lawyer from a law firm to provide legal opinions on the proceedings [3] Group 3: Financial Performance - The company reported a significant increase in sales revenue, with a 29.7% rise to 194,832 million yuan compared to 150,255 million yuan in the previous year [28][32] - The company managed to reduce its operating loss significantly, with a decrease in net loss attributed to improved sales efficiency and cost control measures [34] - The total assets of the company at the end of 2024 were 1,078,196 million yuan, a decrease from 1,134,287 million yuan in 2023 [28][30] Group 4: Governance and Board Activities - The company completed the election of the fourth board of directors on June 21, 2024, with 14 members, including 5 independent non-executive directors [9][11] - The board held 13 meetings during the reporting period, approving all agenda items without any rejections [10] - The board established four specialized committees to enhance governance efficiency and decision-making [10][12] Group 5: Future Plans - The company plans to apply for financing and credit limits totaling up to 8 billion yuan to support its operational and project development needs [39] - The board aims to strengthen its governance structure and enhance compliance management in 2025 [13]